BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Staging
6 results:

  • 1. Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.
    Hu J; Wang Y; Deng L; Yu H; Chen K; Bao W; Chen K; Chen G
    Updates Surg; 2022 Oct; 74(5):1589-1599. PubMed ID: 35713784
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma.
    Ge D; Luo Z; Mao R; Zhao H; Lv X; Zhao J; Zhou J; Huang Z; Zhang Y; Li Z; Bi X; Cai J
    Adv Ther; 2020 Jul; 37(7):3185-3205. PubMed ID: 32436026
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission.
    Rathod PS; Kundargi R; Pallavi VR; Vijay CR; Devi UK; Bafna UD
    Int J Gynecol Cancer; 2015 Nov; 25(9):1737-41. PubMed ID: 26401644
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases.
    Zech CJ; Korpraphong P; Huppertz A; Denecke T; Kim MJ; Tanomkiat W; Jonas E; Ba-Ssalamah A;
    Br J Surg; 2014 May; 101(6):613-21. PubMed ID: 24652690
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report.
    Gardini A; Saragoni L; La Barba G; Serra L; Calistri D; Ulivi P; Casadei A; Frassineti GL; Garcea D
    Pathologica; 2012 Aug; 104(4):177-81. PubMed ID: 23316620
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers.
    Winter JM; Tang LH; Klimstra DS; Brennan MF; Brody JR; Rocha FG; Jia X; Qin LX; D'Angelica MI; DeMatteo RP; Fong Y; Jarnagin WR; O'Reilly EM; Allen PJ
    PLoS One; 2012; 7(7):e40157. PubMed ID: 22792233
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.